TY - JOUR
T1 - Improvement of frontal lobe dysfunction and white matter integrity by rTMS in treatment-resistant depression
AU - Tateishi, Hiroshi
AU - Nishihara, Masashi
AU - Kawaguchi, Atsushi
AU - Matsushima, Jun
AU - Murakawa, Toru
AU - Haraguchi, Yoshinori
AU - Kunitake, Yutaka
AU - Maekawa, Toshihiko
AU - Kato, Takahiro A.
AU - Asami, Toyoko
AU - Mizoguchi, Yoshito
AU - Monji, Akira
N1 - Funding Information:
Dr. Tateishi was supported by the Japan Society for the Promotion of Science (JSPS KAKENHI Grant Number 17K10307).
Publisher Copyright:
© 2019 Tateishi et al.
PY - 2019
Y1 - 2019
N2 - Aim: The impairment experienced by many individuals with depression is closely related to the cognitive symptoms of the disorder. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation method providing a promising technique for improving cognitive symptoms in treatment-resistant depression (TRD). In the present study, we investigated whether a relationship exists between improvements in frontal lobe dysfunction induced by rTMS and improvement of white matter integrity revealed by diffusion tensor imaging (DTI) in TRD patients receiving rTMS treatment. Methods: A total of 12 patients with TRD were enrolled in a high-frequency (10 Hz) rTMS study (August 2013-January 2019). Frontal lobe function and depressive symptoms were assessed at baseline and at the endpoint of rTMS treatment. Fractional anisotropy (FA), as a measure of white matter integrity obtained from DTI, was investigated using a region-ofinterest (ROI) approach. Results: rTMS treatment significantly improved depressive symptom scores and some subscales of frontal lobe dysfunction. Category scores in the Word Fluency Test and scores on part 3 of the Color Stroop Test were improved independently of the improvement of depressive symptoms. In the ROI analysis, none of the FA increases in any region were correlated with improvement of any frontal lobe function (n = 12). Conclusion: Although rTMS resulted in partial improvement of frontal lobe dysfunction as well as white matter integrity, we found no correlation between improved frontal lobe dysfunction and improved white matter integrity in TRD patients.
AB - Aim: The impairment experienced by many individuals with depression is closely related to the cognitive symptoms of the disorder. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation method providing a promising technique for improving cognitive symptoms in treatment-resistant depression (TRD). In the present study, we investigated whether a relationship exists between improvements in frontal lobe dysfunction induced by rTMS and improvement of white matter integrity revealed by diffusion tensor imaging (DTI) in TRD patients receiving rTMS treatment. Methods: A total of 12 patients with TRD were enrolled in a high-frequency (10 Hz) rTMS study (August 2013-January 2019). Frontal lobe function and depressive symptoms were assessed at baseline and at the endpoint of rTMS treatment. Fractional anisotropy (FA), as a measure of white matter integrity obtained from DTI, was investigated using a region-ofinterest (ROI) approach. Results: rTMS treatment significantly improved depressive symptom scores and some subscales of frontal lobe dysfunction. Category scores in the Word Fluency Test and scores on part 3 of the Color Stroop Test were improved independently of the improvement of depressive symptoms. In the ROI analysis, none of the FA increases in any region were correlated with improvement of any frontal lobe function (n = 12). Conclusion: Although rTMS resulted in partial improvement of frontal lobe dysfunction as well as white matter integrity, we found no correlation between improved frontal lobe dysfunction and improved white matter integrity in TRD patients.
UR - http://www.scopus.com/inward/record.url?scp=85074723215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074723215&partnerID=8YFLogxK
U2 - 10.2147/NDT.S228501
DO - 10.2147/NDT.S228501
M3 - Article
AN - SCOPUS:85074723215
SN - 1176-6328
VL - 15
SP - 3079
EP - 3087
JO - Neuropsychiatric Disease and Treatment
JF - Neuropsychiatric Disease and Treatment
ER -
